Speaker Announcement: Dr. Alexander “Sandro” Sulakvelidze Joins JAFRAL Phage Summit 2026 lineup

Dr. Sulakvelidze is widely recognized as a global leader in bacteriophage technology. As the co‑founder of Intralytix, he has played a crucial role in defining the company’s scientific strategy, regulatory path, and strong patent portfolio. Under his leadership, Intralytix has grown into a successful clinical‑stage biotech company with several FDA‑cleared products and active Phase 1/2a clinical trials.

‍

Day 2 Session Highlight

Dr. Sulakvelidze will deliver a talk titled:
“Advancing Phage Therapeutics: Intralytix’s Integrated Discovery‑to‑Clinic Platform.”

In this session, he will present how Intralytix is accelerating the development of phage-based therapeutics—from early research and discovery to real-world clinical applications.

This is a unique opportunity to hear firsthand from one of the leading innovators shaping the future of phage therapy.